Abstract:Protein kinases play pivotal roles in various biological functions, influencing cell differentiation, promoting survival, and regulating the cell cycle. The disruption of protein kinase activity is intricately linked to pathways in tumor development. This manuscript explores the transformative impact of protein kinase inhibitors on cancer therapy, particularly their efficacy in cases driven by targeted mutations. Focusing on key tyrosine kinase inhibitors (TKIs) like Bcr-Abl, Epidermal Growth Factor Receptor (EGFR), and Vascular Endothelial Growth Factor Receptor (VEGFR), it targets critical kinase families in cancer progression. Clinical trial details of these TKIs offer insights into their therapeutic potentials. Learning from FDA-approved kinase inhibitors, the review dissects trends in kinase drug development since imatinib's paradigm-shifting approval in 2001. TKIs have evolved into pivotal drugs, extending beyond oncology. Ongoing clinical trials explore novel kinase targets, revealing the vast potential within the human kinome. The manuscript provides a detailed analysis of advancements until 2022, discussing the roles of specific oncogenic protein kinases in cancer development and carcinogenesis. Our exploration on PubMed for relevant and significant TKIs undergoing pre-FDA approval phase III clinical trials enriches the discussion with valuable findings. While kinase inhibitors exhibit lower toxicity than traditional chemotherapy in cancer treatment, challenges like resistance and side effects emphasize the necessity of understanding resistance mechanisms, prompting the development of novel inhibitors like osimertinib targeting specific mutant proteins. The review advocates thorough research on effective combination therapies, highlighting the future development of more selective RTKIs to optimize patient-specific cancer treatment and reduce adverse events.

Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective

Advances in studies of tyrosine kinase inhibitors and their acquired resistance

Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling.

Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors

Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma

Nanoformulations of small molecule protein tyrosine kinases inhibitors potentiate targeted cancer therapy

Acquired resistance to tyrosine kinase targeted therapy: mechanism and tackling strategies

Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors Associated with Hepatocellular Carcinoma.

EGFR-TKI Resistance in NSCLC Patients: Mechanisms and Strategies.

FGFR-TKI Resistance in Cancer: Current Status and Perspectives

Mechanism and Treatment Associated with Resistance to EGFR-TKI

Advances in Small-Molecule Inhibitors of Protein Tyrosine Kinases

Promoting reactive oxygen species accumulation to overcome tyrosine kinase inhibitor resistance in cancer

Non-Receptor Tyrosine Kinases: Their Structure and Mechanistic Role in Tumor Progression and Resistance

Protein tyrosine phosphatases: emerging role in cancer therapy resistance

Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma

Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors

Molecular Mechanism and Therapeutic Strategy for Resistance to Tyrosine Kinase Inhibitors in Targeted Treatment of Gastrointestinal Stromal Tumors

Drug Resistant Mechanism of Small Molecular Tyrosine Kinase Inhibitors

Molecular Mechanisms of Tumor Resistance to PI3K-mTOR-targeted Therapy

Tyrosine kinase inhibitors in cancers: Treatment optimization - Part I